Navigation Links
Chemo Combination Improves Survival in Asbestos-Related Cancer

unt for 65,000 deaths between 2001 and 2050 worldwide, peaking between 2012 and 2015, according to background information in the review.

It is a personal matter as to whether the survival increase for patients receiving the two drugs is worthwhile, Baram said. “It depends in large part on the patient. A 2.8-month mean survival increase means that some patients may get even more than that, though some people will get less. Many, if not most, patients when faced with a disease with a very bad prognosis are often willing to undergo aggressive therapy, although the toxicity is serious and potentially life-threatening.”

Souce-Newswise
SRM
'"/>




Page: 1 2 3

Related medicine news :

1. Acupuncture May Help Chemotherapy Side Effects
2. Chemotherapy Pill Has Fewer Side Effects Than IV
3. Survival rates in breast cancer patients improved with "Dose Dense Chemotherapy"
4. Therapy Boosts Chemotherapy Effects
5. Chemotherapy Effective for Bladder Cancer
6. Hope for Chemo-Resistant Leukemia Patients
7. New Method Of Delivering Chemotherapy
8. Drug That Is Found To Reduce Heart Damage from Chemo
9. The Benefits Of Chemotherapy For Women With Ovarian Cancer
10. New Compound Could Strengthen The Effect Of Chemotherapy
11. Older Breast Cancer Patients Can Be Effectively Treated With Chemotherapy
Post Your Comments:
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 1GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 2GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 3GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 4GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 5GeoVax Labs Inc Celebrates 21st World AIDS Day With Continued Clinical Trial Progress 15013 6nContact Announces Initiation of Clinical Trials for the Treatment of Paroxysmal Atrial Fibrillation Utilizing New Convergent Ablation Procedure 6632 1nContact Announces Initiation of Clinical Trials for the Treatment of Paroxysmal Atrial Fibrillation Utilizing New Convergent Ablation Procedure 6632 2MedQuist Integrates Search Engine from Primordial with SpeechQ 28TM 29 for Radiology 6630 1MedQuist Integrates Search Engine from Primordial with SpeechQ 28TM 29 for Radiology 6630 2